Pharminent · Daily Brief
November 13, 2026
Regulatory & Approvals
Lilly Wins China Approval for Oral GLP-1 Weight Loss Drug
China’s NMPA approved Lilly’s oral GLP-1 receptor agonist Foundayo for weight management, the first regulatory authorization of an oral weight loss drug in China.
Pharmaceutical Technology →$LLY
CHMP Recommends Seven New Medicines at November Meeting
The EMA’s Committee for Medicinal Products for Human Use recommended seven new medicines for approval at its November 9-12, 2026 meeting, including aumolertinib (Aumseqa) from SFL Pharmaceuticals Deutschland, AstraZeneca’s baxdrostat (Baxfendy) for hypertension in adults, and sintilimab (Zybrivo).
EMA →$AZN
FDA Pauses Commissioner’s National Priority Voucher Framework
The FDA has put its commissioner’s priority voucher framework on hold, following consistent questions from experts about how the vouchers were awarded and their wider industry benefits.
Pharmaceutical Technology →
FDA Has More Than 1,000 Open Jobs Amid Staffing Shortage
The FDA has over 1,000 open positions as it continues to recover from a mass staff departure last year that left the agency shorthanded, with effects on drug reviews for industry.
BioPharma Dive →
Clinical Data
Scientists Publish Most Detailed Map Yet of the Basal Ganglia
A large scientific collaboration produced the most detailed map to date of the basal ganglia, a brain region involved in a range of psychiatric and neurologic disorders.
STAT →
Deals & Partnerships
Blackstone to Fund Pfizer’s Berobenatide Trials With Up to $1.5B
Blackstone Life Sciences signed a co-funding deal providing Pfizer up to $1.5 billion to support a Phase 3 program for berobenatide, a monthly-dosed GLP-1 drug for obesity. The drug came from Metsera, which Pfizer acquired last year in a deal worth up to $10 billion.
BioPharma Dive →$PFE
Business & Finance
Windward Prices $175M IPO to Fund China-Licensed Lung Drugs
Swiss biotech Windward priced a $175 million IPO to advance two China-licensed respiratory candidates it says could outcompete AstraZeneca and Amgen’s asthma treatment Tezspire.
BioPharma Dive →$AZN$AMGN
Neurosterix Raises $105M for Schizophrenia Candidate
Neurosterix raised $105 million to fund its schizophrenia candidate, leading the week’s biotech financings. Delix, VectorY and Eli Radiopharma also added to their cash reserves.
Pharmaphorum →
WHO Report Says Tuberculosis Killed Over a Million People in 2025
The WHO’s 2026 Global Tuberculosis Report found that more than a million people died of tuberculosis in 2025, alongside a drop in international donor funding.
Forbes →
Forwarded this? Get your copy free
Sign up free →
Pharminent — Competitive Intelligence Suite · Tickers link to Yahoo Finance for reference only. Editorial framings are analysis, not investment advice. © 2026.